Longitudinal Changes in Multiple Cardiac Biomarkers in Transthyretin Amyloidosis Cardiomyopathy Patients Treated Vs Untreated with Tafamidis

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Karan Shahi MSc , Robert J.H. Miller MD , Steven Dykstra PhD , Yuanchao Feng PhD , Jonathan G. Howlett MD , Victor Jimenez-Zepeda MD , Jan Veenhuyzen RN, BScN , James A. White MD , Nowell M. Fine MD, SM
{"title":"Longitudinal Changes in Multiple Cardiac Biomarkers in Transthyretin Amyloidosis Cardiomyopathy Patients Treated Vs Untreated with Tafamidis","authors":"Karan Shahi MSc ,&nbsp;Robert J.H. Miller MD ,&nbsp;Steven Dykstra PhD ,&nbsp;Yuanchao Feng PhD ,&nbsp;Jonathan G. Howlett MD ,&nbsp;Victor Jimenez-Zepeda MD ,&nbsp;Jan Veenhuyzen RN, BScN ,&nbsp;James A. White MD ,&nbsp;Nowell M. Fine MD, SM","doi":"10.1016/j.cjco.2025.05.012","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Tafamidis is an oral transthyretin stabilizer that improves survival in transthyretin amyloidosis cardiomyopathy (ATTR-CM), but only limited real-world data describe serial cardiac biomarker changes following treatment initiation. The primary objective of this study was to characterize longitudinal changes across multiple cardiac biomarker domains in tafamidis-treated ATTR-CM patients, to describe how these parameters evolve over time in routine clinical practice. We also report the same outcomes in untreated patients to reflect the natural disease history in a modern real-world cohort.</div></div><div><h3>Methods</h3><div>Clinical, biochemical, and cardiac imaging parameters were serially assessed at baseline and 1-year follow-up for 145 ATTR-CM patients, both those treated and those untreated with tafamidis.</div></div><div><h3>Results</h3><div>The median age was 80 years (range: 73-86), and 80 patients (55%) received tafamidis. At baseline, the treated group was younger and exhibited less advanced disease, relative to the untreated group. Treatment with tafamadis was associated with stabilization in N-terminal pro-B-type natriuretic peptide (NTproBNP) level, troponin-T level, and New York Heart Association functional class at 1-year follow-up, whereas the untreated group demonstrated worsening (all comparisons <em>P</em> &lt; 0.05). Tafamidis treatment status was not significantly associated with National Amyloidosis Center or Mayo Clinic disease stage.</div></div><div><h3>Conclusions</h3><div>NTproBNP level, troponin-T level, and New York Heart Association functional class remain stable over 1 year in a real-world cohort of tafamidis-treated ATTR-CM patients. These results may help inform therapeutic monitoring strategies in clinical practice.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 9","pages":"Pages 1190-1197"},"PeriodicalIF":2.5000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CJC Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589790X25003932","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Tafamidis is an oral transthyretin stabilizer that improves survival in transthyretin amyloidosis cardiomyopathy (ATTR-CM), but only limited real-world data describe serial cardiac biomarker changes following treatment initiation. The primary objective of this study was to characterize longitudinal changes across multiple cardiac biomarker domains in tafamidis-treated ATTR-CM patients, to describe how these parameters evolve over time in routine clinical practice. We also report the same outcomes in untreated patients to reflect the natural disease history in a modern real-world cohort.

Methods

Clinical, biochemical, and cardiac imaging parameters were serially assessed at baseline and 1-year follow-up for 145 ATTR-CM patients, both those treated and those untreated with tafamidis.

Results

The median age was 80 years (range: 73-86), and 80 patients (55%) received tafamidis. At baseline, the treated group was younger and exhibited less advanced disease, relative to the untreated group. Treatment with tafamadis was associated with stabilization in N-terminal pro-B-type natriuretic peptide (NTproBNP) level, troponin-T level, and New York Heart Association functional class at 1-year follow-up, whereas the untreated group demonstrated worsening (all comparisons P < 0.05). Tafamidis treatment status was not significantly associated with National Amyloidosis Center or Mayo Clinic disease stage.

Conclusions

NTproBNP level, troponin-T level, and New York Heart Association functional class remain stable over 1 year in a real-world cohort of tafamidis-treated ATTR-CM patients. These results may help inform therapeutic monitoring strategies in clinical practice.
多心脏生物标志物在经甲状腺蛋白淀粉样变性心肌病患者治疗与未治疗他法非地的纵向变化
tafamidis是一种口服转甲状腺素稳定剂,可提高转甲状腺素淀粉样变性心肌病(atr - cm)患者的生存率,但只有有限的实际数据描述了治疗开始后心脏生物标志物的一系列变化。本研究的主要目的是表征他非他汀治疗的atr - cm患者多个心脏生物标志物域的纵向变化,描述这些参数在常规临床实践中如何随时间演变。我们还报告了未经治疗的患者的相同结果,以反映现代现实世界队列中的自然病史。方法对145例atr - cm患者进行基线和1年随访时的临床、生化和心脏影像学参数的连续评估。结果中位年龄为80岁(范围:73 ~ 86岁),80例(55%)患者接受了他法非迪治疗。在基线时,与未治疗组相比,治疗组更年轻,疾病进展更少。在1年随访中,他法马地治疗与n端前b型利钠肽(NTproBNP)水平、肌钙蛋白-t水平和纽约心脏协会功能等级的稳定相关,而未治疗组表现出恶化(所有比较P <; 0.05)。他法非底的治疗状态与国家淀粉样变性中心或梅奥诊所的疾病分期无显著相关性。结论:sntprobnp水平、肌钙蛋白-t水平和纽约心脏协会功能分级在他非他汀治疗atr - cm患者的真实队列中保持稳定超过1年。这些结果可能有助于为临床实践中的治疗监测策略提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CJC Open
CJC Open Medicine-Cardiology and Cardiovascular Medicine
CiteScore
3.30
自引率
0.00%
发文量
143
审稿时长
60 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信